(0.34%) 5 117.06 points
(0.33%) 38 365 points
(0.37%) 15 987 points
(-0.95%) $83.05
(5.56%) $2.03
(0.33%) $2 354.90
(0.47%) $27.67
(4.05%) $959.45
(-0.25%) $0.932
(-0.42%) $10.98
(-0.58%) $0.796
(1.69%) $93.43
@ $0.410
発行日: 13 2月 2024 @ 06:00
リターン: 636.93%
Live Chart Being Loaded With Signals
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases...
Stats | |
---|---|
本日の出来高 | 26 564.00 |
平均出来高 | 96 245.00 |
時価総額 | 65.81M |
EPS | $0 ( 2024-04-02 ) |
次の収益日 | ( $-0.140 ) 2024-05-27 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.290 |
ATR14 | $0.0270 (0.89%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-13 | Fletcher Kyle | Sell | 20 | Class A Common Stock |
2024-04-13 | Haines John R | Sell | 576 | Class A Common Stock |
2024-04-13 | Beers David C | Sell | 360 | Class A Common Stock |
2024-04-13 | Hariri Robert J | Sell | 1 154 | Class A Common Stock |
2024-04-13 | Brigido Stephen | Sell | 268 | Class A Common Stock |
INSIDER POWER |
---|
57.07 |
Last 98 transactions |
Buy: 89 262 897 | Sell: 26 354 903 |
ボリューム 相関
Celularity Inc. 相関
10 最も負の相関 | |
---|---|
CBAY | -0.935 |
TIOA | -0.926 |
CITE | -0.922 |
FXCO | -0.917 |
BWC | -0.915 |
XPDB | -0.915 |
BRIV | -0.914 |
TIOAU | -0.914 |
ROCL | -0.914 |
ITAQ | -0.912 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Celularity Inc. 相関 - 通貨/商品
Celularity Inc. 財務諸表
Annual | 2022 |
収益: | $17.98M |
総利益: | $-1.69M (-9.40 %) |
EPS: | $1.010 |
FY | 2022 |
収益: | $17.98M |
総利益: | $-1.69M (-9.40 %) |
EPS: | $1.010 |
FY | 2021 |
収益: | $21.34M |
総利益: | $17.69M (82.90 %) |
EPS: | $-12.49 |
FY | 2020 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-0.0215 |
Financial Reports:
No articles found.
Celularity Inc.
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。